IDSA and HIVMA Warn Proposed NIAID Restructuring Threatens U.S. Infectious Disease Research and HIV Response
核心洞察
IDSA and HIVMA raised alarm over an Aug. 28 NIH notice proposing a major overhaul of NIAID's clinical research program with few details and a brief comment period.
The restructuring follows months of delays in NIH renewal notices for NIAID clinical trial networks and Centers for AIDS Research, with HIV (搜索) network renewals still pending.
The societies warn that destabilizing NIAID's HIV (搜索) research infrastructure will harm study participants and compromise the U.S. infectious disease response amid worsening workforce shortages.
The Infectious Diseases Society of America (搜索) (IDSA) and the HIV Medicine Association (搜索) (HIVMA) are raising concerns over a notice released Aug. 28 by the National Institutes of Health (NIH) announcing a proposed overhaul of the National Institute of Allergy and Infectious Diseases' (NIAID) clinical research program, citing a lack of detail and an abbreviated comment period. The organizations argue that changes of this magnitude warrant a lengthier and more meaningful opportunity for input from researchers, clinicians, community partners, and other stakeholders, including Congress.
Proposed Restructuring Follows Months of Renewal Delays
The proposed restructuring comes after many months of delays in NIH issuing renewal notices for NIAID's clinical trial networks and Centers for AIDS Research (CFARs), whose discoveries helped establish the United States as a leader in biomedical research worldwide. According to IDSA and HIVMA, renewal notices for the infectious diseases (ID) networks were finally released this week, but ongoing delays in the renewals for the pioneering CFARs and HIV (搜索) clinical trial networks remain alarming.
Impact on Study Participants and Public Health Infrastructure
IDSA and HIVMA warn that destabilizing NIAID's HIV (搜索) research infrastructure will harm study participants and further compromise the country's infectious diseases response at a time when ID workforce shortages are worsening and front-line public health systems are eroding due to funding cuts and staffing shortages.
The societies emphasize that the expertise and stability of NIAID's HIV (搜索) research networks and centers have fueled discoveries that have saved millions of lives by preventing and treating HIV and other infectious diseases, including viral hepatitis and tuberculosis (搜索). These advances include developing HIV antiretrovirals that suppress the virus to undetectable levels and are 99% effective at preventing HIV acquisition, laying the groundwork for a cure for hepatitis C (搜索), and identifying shorter treatment regimens for tuberculosis, described as the deadliest infectious disease worldwide.
Call to Action on Funding and Oversight
IDSA and HIVMA call on NIH to prioritize the health and biosecurity of Americans by immediately releasing the HIV (搜索) clinical research networks and centers notices of funding opportunities, and by providing extensions where needed to protect study participants and ensure research in clinical trials underway is not lost. The organizations also urge Congress to conduct the oversight necessary to prevent the dismantling of decades of investments in the nation's biomedical research infrastructure.
Bipartisan Continuing Resolution Blocks Proposed Grant Rule
In a separate statement, IDSA and HIVMA applauded Congress for its swift and overwhelmingly bipartisan approval of a continuing resolution to fund the government and block the White House Office of Management and Budget from finalizing or implementing its proposed "Regulation for Federal Financial Assistance" until Dec. 11.
The proposed rule would overhaul federal grant processes, replacing peer review, scientific merit, and patient needs with political alignment, and would upend federal support for medical research and public health with what the societies describe as devastating consequences that would leave the nation far more vulnerable to infectious diseases and put ending the HIV (搜索) epidemic further out of reach.
The societies call upon Congress to enact a long-term solution to protect the patients, communities, clinicians, and researchers who rely on federally funded research to deliver lifesaving prevention and treatment and public health infrastructure to prevent and track serious health threats. The statements were issued by Ronald G. Nahass, MD, MHCM, FIDSA, President of IDSA, and Anna K. Person, MD, FIDSA, Chair of HIVMA.